Takeda Pharmaceutical (TAK) Gross Profit (2017 - 2026)

Takeda Pharmaceutical's Gross Profit history runs 10 years deep, the most recent figure standing at $4.4 billion for Q1 2026.

• On a quarterly basis, Gross Profit fell 18.38% year-over-year to $4.4 billion in Q1 2026; TTM through Mar 2026 was $30.1 billion, a 1.17% decrease from a year earlier, with the FY2026 full-year figure at $19.5 billion, up 261.65% from the prior year.
• Gross Profit fell to $4.4 billion in Q1 2026 per TAK's latest filing, from $4.5 billion in the prior quarter.
• Across five years, Gross Profit topped out at $15.8 billion in Q3 2025 and bottomed at $4.4 billion in Q1 2026.
• The 5-year median for Gross Profit is $5.4 billion (2022), against an average of $7.5 billion.
• Across the five-year window, Gross Profit surged 199.34% in 2022 and decreased 18.38% in 2026, its largest moves.
• Year by year, Gross Profit stood at $4.6 billion in 2022, then decreased by 1.17% to $4.5 billion in 2023, then fell by 2.35% to $4.4 billion in 2024, then gained by 1.36% to $4.5 billion in 2025, then declined by 1.86% to $4.4 billion in 2026.
• Per Business Quant, the three latest TAK Gross Profit figures stand at $4.4 billion (Q1 2026), $4.5 billion (Q4 2025), and $15.8 billion (Q3 2025).